Antengene Receives the US FDA’s IND Clearance of ATG-031 for Advanced Solid Tumors or B-Cell Non-Hodgkin's Lymphoma
- The US FDA has cleared an IND application to initiate the P-I (PERFORM) dose-finding study of ATG-031 for advanced solid tumors or B-NHL
- The primary objective of the study is to evaluate ATG-031's safety & tolerability as a monotx. and to select the right dose for P-II studies while the secondary objective is to characterize ATG-031's pharmacology, examine its immunogenicity & evaluate the preliminary efficacy
- ATG-031, a humanized anti-CD24 mAb, blocks the "don't eat me" signal in the TME. The goal of the treatment is to increase macrophage-mediated phagocytosis of cancer cells & improve the activity of cytotoxic T cells in TME by binding with the CD24 expression on cancer cells with high affinity & blocking the connection b/w CD24 & Siglec-10 receptor
Ref: PRNewswire | Image: Antengene
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.